[The effect of cyclic administration of progestagens on blood coagulation factors].
The relationship between thromboembolism and oral contraceptives has been discussed for 30 years. Recently, a new actuality for this problem has grown up. The estrogen component of the preparations seems to be the cause, but some authors also think of the progestogens as responsible for drug-related thromboembolic disorders. In 31 patients with mastopathy or mastodynia, who had been treated with 10 mg medrogeston of dydrogesteron for six cycles, there were no significant changes in the parameters of hemostasis and fibrinolysis. Especially, we did not find any indications to an activation of the coagulation system. There is no evidence for a thrombogenetic effect caused by the cyclic therapy with these progestogens.
Winkler
U H
UH
Abteilung für Gynäkologie/gynäkologische Onkologie, Universitätsklinikum Essen.
Lauck
U S
US
Ebert
C
C
Schindler
A E
AE
D000293:Adolescent; D000328:Adult; D001779:Blood Coagulation Factors / Q000187:drug effects*; D001941:Breast Diseases / Q000188:drug therapy* / Q000503:physiopathology; D004394:Dydrogesterone / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D008524:Medrogestone / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D008875:Middle Aged; D010146:Pain / Q000188:drug therapy; D011247:Pregnancy; D045167:Progesterone Congeners / Q000008:administration & dosage / Q000493:pharmacokinetics / Q000627:therapeutic use*
D001779:Blood Coagulation Factors; D045167:Progesterone Congeners; D008524:Medrogestone; D004394:Dydrogesterone
Der Einfluss zyklisch verabreichter Gestagene auf die plasmatischen Gerinnungsfaktoren.